Gene therapy in autoimmune, demyelinating disease of the central nervous system

Gene Therapy

Volumn 10, Issue 10, 2003, Pages 844-853

  Baker, David ^a   Hankey, D J R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmunity; Cytokines; Experimental allergic encephalomyelitis; Gene therapy; Multiple sclerosis; Neurodegeneration

Indexed keywords

ADENOVIRUS VECTOR; ANTIINFLAMMATORY AGENT; ANTISENSE OLIGONUCLEOTIDE; BETA INTERFERON; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; LIPOSOME; NAKED DNA; NERVE GROWTH FACTOR; PLASMID DNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VACCINIA VACCINE;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; DEMYELINATING DISEASE; DNA VECTOR; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENCEPHALOMYELITIS; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; LEUKOCYTE ACTIVATION; MOUSE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RAT; REVIEW; VACCINATION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM;

ADOPTIVE TRANSFER; ANIMALS; CENTRAL NERVOUS SYSTEM; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MULTIPLE SCLEROSIS; TH1 CELLS; VACCINES, DNA;

ADENOVIRIDAE; ANIMALIA; HERPES; SIMPLEXVIRUS; VACCINIA; VACCINIA VIRUS;

EID: 0038823638     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302025     Document Type: Review

References (122)

1. Raine CS, McFarland HF, Tourtellotte WW (eds). Multiple Sclerosis. Clinical and Pathogenetic Basis. Chapman & Hall: London, 1997.
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2002; 359: 1221-1231. MEDLINE
3. Compston A, Sawcer S. Genetic analysis of multiple sclerosis. Curr Neurol Neurosci Rep 2002; 2: 259-266. MEDLINE
4. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85-95. MEDLINE.
5. Olson JK, Eagar TN, Miller SD. Functional activation of myelin-specific T cells by virus-induced molecular mimicry. J Immunol 2002; 169: 2719-2726. MEDLINE.
6. van Noort JM, Bajramovic JJ, Plomp AC, van Stipdonk MJ. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol. 2000; 105: 46-57. MEDLINE
7. Alvord ECJ, Kies MW, Suckling AJ (eds). Experimental Allergic Encephalomylitis: A Useful Model For Multiple Sclerosis. Allen R Liss: New York, 1984.
8. Flugel A et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity. 2001; 14: 547-560. MEDLINE
9. Butter C, Baker D, O'Neill JK, Turk JL. Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice. J Neurol Sci. 1991; 104: 9-12. MEDLINE
10. Karin N et al. Selective and nonselective stages in homing of T lymphocytes to the central nervous system during experimental allergic encephalomyelitis. J Immunol 1993; 150: 4116-4124. MEDLINE.
11. Steinman L et al. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci. 2002; 25: 491-505. MEDLINE.
12. Baker D, Gibjels K, Steinman LS. Cytokines in multiple sclerosis. In: The Role of Cytokines in Autoimmunity. Brennan FO, Feldmann M (eds). RG Landes Company: Austin, 1996. pp 77-99.
13. Issazadeh S et al. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta. J Neuroimmunol 1995; 61: 205-212. Article MEDLINE
14. Kennedy MK, Torrance DS, Picha KS, Mohler KM. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992; 149: 2496-2505. MEDLINE
15. Baranzini SE et al. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol. 2000; 165: 6576-6582. MEDLINE
16. Lock C et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 500-508. MEDLINE
17. Romagnani S. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol. 2000; 85: 9-18. MEDLINE
18. Ando DG et al. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 1989; 124: 132-143. MEDLINE
19. Youssef S et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84. MEDLINE
20. Brok HP et al. Non-human primate models of multiple sclerosis. Immunol Rev. 2001; 183:173-185. MEDLINE
21. Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995; 181: 381-386. MEDLINE
22. Falcone M, Rajan A, Bloom B, Brosnan C. A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4 deficient C57BL/6 and BALB/c mice. J Immunol 1998; 160: 4822-4830. MEDLINE
23. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994; 24: 1434-1440. MEDLINE
24. Samoilova E, Horton J, Chen Y. Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice: roles of interleukin-10 in disease progression and recovery Cell Immunol 1998; 188: 118-124. MEDLINE
25. Chen Y et al. Regulatory T-cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237-1240. MEDLINE
26. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002; 16: 183-200. MEDLINE
27. Calabresi PA et al. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology 1998; 51: 289-292. MEDLINE
28. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894. MEDLINE
29. The Lenercept Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457-465 .
30. van Oosten BW et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 7: 1531-1534.
31. Saunders NR, Habgood MD, Dziegielewska KM. Barrier mechanisms in the brain, I. Adult brain. Clin Exp Pharmacol Physiol 1999; 26: 11-19. MEDLINE
32. Waisman A et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity Nature Med 1996; 2: 899-905. MEDLINE
33. Youssef S et al. Long lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol 1998; 161: 3870-3879. MEDLINE
34. Croxford JL et al. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol 1998; 160: 5181-5187. MEDLINE
35. Piccirillo CA, Prud'homme GJ. Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors. Hum Gene Ther 1999; 10: 1915-1922. MEDLINE
36. Lobell A et al. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis. J Immunol 1999; 163: 4754-4762. MEDLINE
37. Weissert R et al. Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen. Proc Natl Acad Sci USA 2000; 97: 1689-1694. MEDLINE
38. Garren H et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 2001; 15: 15-22. MEDLINE
39. Wildbaum G, Netzer N, Karin N. Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T-cell polarization and suppresses experimental autoimmune encephalomyelitis. J Immunol 2002; 168: 5885-5892. MEDLINE
40. Lobell A et al. Suppressive DNA Vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response. J Immunol 2003; 170: 1806-1813. MEDLINE
41. Soilu-Hanninen M et al. Treatment of experimental autoimmune encephalomyelitis with antisense oligonucleotides against the low affinity neurotrophin receptor. J Neurosci Res 2000; 59: 712-721. MEDLINE
42. Willenborg DO, Fordham SA, Cowden WB, Ramshaw IA. Cytokines and murine autoimmune encephalomyelitis: inhibition or enhancement of disease with antibodies to select cytokines, or by delivery of exogenous cytokines using a recombinant vaccinia virus system. Scand J Immunol 1995; 41: 31-41. MEDLINE
43. Croxford JL et al. Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis. Eur J Immunol 1998; 28: 3904-3916. MEDLINE
44. Guy J, Qi X, Wang H, Hauswirth WW. Adenoviral gene therapy with catalase suppresses experimental optic neuritis. Arch Ophthalmol 1999; 117: 1533-1539. MEDLINE
45. Kawaguchi Y. A gene therapy or purified CTLA4IgG treatment of experimental allergic encephalomyelitis. Hokkaido Igaku Zasshi 1999; 74: 467-475. MEDLINE
46. Cua DJ et al. Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J Immunol 2001; 166: 602-608. MEDLINE
47. Croxford JL, Feldmann M, Chernajovsky Y, Baker D. Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J Immuno 2001; 166: 4124-4130. MEDLINE
48. Furlan R et al. Central nervous system delivery of interleukin-4 by a non-replicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. Hum Gene Ther 1998; 9: 2605-2617. MEDLINE
49. Ruffini F et al. Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther. 2000; 8: 1207-1213. MEDLINE
50. Broberg E et al. Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis. Gene Ther. 2001; 8: 769-777. MEDLINE
51. Furlan R et al. Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Ther 2001; 8: 13-19. MEDLINE
52. Furlan R et al. Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol 2001; 167: 1821-1829. MEDLINE
53. Poliani PL et al. Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum Gene Ther 2001; 12: 905-920. MEDLINE
54. Croxford JL et al. Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor. J Immunol 2001; 164: 2776-2781. MEDLINE
55. Mathisen PM et al. Treatment of experimental autoimmune, encephalomyelitis with genetically modified memory T cells. J Exp Med 1997; 186: 159-164. MEDLINE
56. Shaw MK et al. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J Exp Med 1997; 185: 1711-1714. MEDLINE
57. Mathisen PM et al. Th2 T cells expressing transgene PDGF-A serve as vectors for gene therapy in autoimmune demyelinating disease. J Autoimmun 1999; 13: 31-38. MEDLINE
58. Chen LZ et al. Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-β1. Proc Natl Acad Sci USA 1998; 95: 12516-12521. MEDLINE
59. Dal Canto RA et al. Local delivery of cytokines by retrovirally transduced antigen-specific TCR hybridoma cells in experimental autoimmune encephalomyelitis. Eur Cytokine Netw 1998; 9: 83-91. MEDLINE
60. Dal Canto RA et al. Local delivery of TNF by retrovirus-transduced T lymphocytes exacerbates experimental autoimmune encephalomyelitis. Clin Immunol 1999; 90: 10-14. MEDLINE
61. Flugel A et al. Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur J Immunol 2001; 31: 11-22. MEDLINE
62. Chen C et al. A gene therapy approach for treating T-cell-mediated autoimmune diseases. Blood 2001; 97: 886-894. MEDLINE
63. Melo ME et al. Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol 2002; 168: 4788-4795. MEDLINE
64. Martino G, Furlan R, Comi G, Adorini L.The ependymal route to the CNS: an emerging gene-therapy approach for MS. Trends Immunol 2001; 22: 483-490. MEDLINE
65. Becher B, Durell BG, Noelle RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002; 110: 493-497. MEDLINE
66. Schapiro RT. M anagement of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. Curr Neurol Neurosci Rep 2001; 1: 299-302. MEDLINE
67. Martino G et al. Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach. J Neuroimmunol 2000; 107: 184-190. MEDLINE
68. Allen SJ et al. Isolation and characterization of cells infiltrating the spinal cord during the course of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse. Cell Immunol 1993; 146: 335-350. MEDLINE
69. Boccaccio GL, Mor F, Steinman L. Noncoding plasmid DNA induces IFN-γ in vivo and suppresses autoimmune encephalomyelitis. Int Immunol 1999; 11: 289-296. MEDLINE
70. Tsunoda I et al. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA. Brain Pathol 1999; 9: 481-493. MEDLINE
71. Shimeld C et al. Cytokine production in the nervous system of mice during acute and latent infection with herpes simplex virus type 1. J Gen Virol 1997; 78: 3317-3325. MEDLINE
72. Modo M et al. Transplantation of neural stem cells in a rat model of stroke: assessment of short-term graft survival and acute host immunological response. Brain Res 2002; 958: 70-82. MEDLINE
73. Thomas CE et al. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci USA 2000; 97: 7482-7487. MEDLINE
74. Ali RR et al. Co-injection of adenovirus expressing CTLA4-Ig prolongs adenovirally mediated lacZ reporter gene expression in the mouse retina. Gene Ther 1998; 5: 1561-1565. MEDLINE
75. Lowenstein PR. Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol 2002; 23: 23-30. M . MEDLINE
76. Cao Q, Benton RL, Whittmore SR. Stem cell repair of central nervous system injury. J Neurosci Res 2002; 68: 501-510. MEDLINE
77. Dezawa M. Central and peripheral nerve regeneration by transplantation of Schwann cells and transdifferentiated bone marrow stromal cells. Anat Sci Int 2002; 77: 12-25. MEDLINE
78. Galvin KA, Jones DG. Adult human neural stem cells for cell-replacement therapies in the central nervous system. Med J Aust 2002; 177: 316-318. MEDLINE
79. Franklin RJ. Remyelination of the demyelinated CNS: the case for and against transplantation of central, peripheral and olfactory glia. Brain Res Bull 2002; 57: 827-832. MEDLINE
80. Chari DM, Blakemore WF.New insights into remyelination failure in multiple sclerosis: implications for glial cell transplantation. Mult Scler 2002; 8: 271-277. MEDLINE
81. Aebischer P et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996; 2: 696-699. MEDLINE
82. Yura M et al. Role of MOG-stimulated Th1 type 'light up' (GFP+) CD4+ T cells for the development of experimental autoimmune encephalomyelitis (EAE). J Autoimmun 2001; 17: 17-25. MEDLINE
83. Pette M et al. M yelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990; 40: 1770-1776. MEDLINE
84. van Noort JM et al. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995; 375: 798-801. MEDLINE
85. Nicholson LB et al. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995; 3: 397-405. MEDLINE
86. Young DA et al. IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J Immunol 2000; 164: 3563-3572. MEDLINE
87. Kim HJ et al. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin Immunol 2002; 104: 105-114. MEDLINE
88. Chernajovsky Y et al. Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor. Gene Ther 1995; 2: 731-735.
89. Robinson WH, Garren H, Utz PJ, Steinman L. Millennium Award. Proteomics for the development of DNA tolerizing vaccines to treat autoimmune disease. Clin Immunol 2002; 103: 7-12. MEDLINE
90. Acha-Orbea et al. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 1988; 54: 263-273. MEDLINE
91. Kuchroo VK et al. Experimental allergic encephalomyelitis mediated by cloned T cells specific for a synthetic peptide of myelin proteolipid protein. Fine specificity and T cell receptor V beta usage. J Immunol 1992; 148: 3776-3782. MEDLINE
92. Vandenbark AA et al. TCR peptide therapy in human autoimmune diseases. Neurochem Res 2001; 26: 713-730. MEDLINE
93. Jones RE et al. Epitope spreading is not required for relapses in experimental autoimmune encephalomyelitis. J Immunol 2003; 170: 1690-1698. MEDLINE
94. O'Neill JK et al. Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier: elucidation by the action of Brequinar sodium. J Neuroimmunol 1992; 38: 53-62. MEDLINE
95. O'Neill JK, Baker D, Turk JL. Inhibition of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse. J Neuroimmunol 1992; 41: 177-187. MEDLINE
96. Morris-Downes MM et al. Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice. J Neuroimmunol 2002; 125: 114-124. MEDLINE
97. Pedotti R et al. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol 2001; 2: 216-222. MEDLINE
98. Genain CP et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996; 274: 2054-2057. MEDLINE
99. Bielekova B et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167-1175. MEDLINE
100. Kappos L et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000; 6: 1176-1182. MEDLINE
101. Coles AJ et al. M onoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304. MEDLINE
102. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003; 206: 165-171. MEDLINE
103. Wujek JR et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol 2002; 61: 23-32. MEDLINE
104. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001; 50: 169-180. MEDLINE
105. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000; 6: 67-70. MEDLINE
106. Lo AC, Black JA, Waxman SG. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. Neuroreport 2002; 13: 1909-1912. MEDLINE
107. Kapoor R et al. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 2003; 53: 174-180. MEDLINE
108. Stankoff B et al. Ciliary neurotrophic factor (CNTF) enhances myelin formation: a novel role for CNTF and CNTF-related molecules. J Neurosci 2002; 22: 9221-9227. MEDLINE
109. Wang LJ et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 2002; 22: 6920-6928.
110. Alberch J, Perez-Navarro E, Canals JM. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Res Bull 2002; 57: 817-822. MEDLINE
111. Markert J et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy 2000; 7: 867-874. MEDLINE
112. Lock C, Oksenberg J, Steinman L. The role of TNF alpha and lymphotoxin in demyelinating disease. Ann Rheum Dis 58(Suppl 1): 1121-1128. MEDLINE
113. Steinman L. M yelin-specific CD8 T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis. J Exp Med 2001; 194: F27-F30. MEDLINE
114. Correale J et al. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol 1995; 154: 2959-2968. MEDLINE
115. Neuhaus O et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 2002; 59: 990-997. MEDLINE
116. Chu CQ, Wittmer S, Dalton DK. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med 2000; 192: 123-128. MEDLINE
117. Panitch NL, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1: 893-895. MEDLINE
118. Skurkovich S. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Mult Scler 2001; 7: 277-2784. MEDLINE
119. Hueseby ES et al. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 2001; 194: 669-676. MEDLINE
120. Sun D et al. M yelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 2001; 166: 7579-7587. MEDLINE
121. Babbe H et al. clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192: 393-404. MEDLINE
122. Jacobsen M et al. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002; 125: 538-550. MEDLINE